Bicycle Therapeutics

Peptide
#Bayer #Bicycle Therapeutics #Collaboration #Oncology #Partnership #Peptides #Radiochemistry

Bayer and Bicycle collaborate on bicyclic peptides

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity,… Read More

#Cancer Research #News

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News